{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-015590","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2026-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.433929+00:00","generated_at":"2026-05-14T21:39:38.216710+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety","bullets":["Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.","R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.","G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.","PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.","ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-015590","json":"https://secwatch.observer/filing/0001437749-26-015590.json","markdown":"https://secwatch.observer/filing/0001437749-26-015590.md","text":"https://secwatch.observer/filing/0001437749-26-015590.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/0001437749-26-015590-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/phio20260331_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:39:38.216710+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c434e2e3e9e4ee2ce75df4aa8cc1a17f168abde","claim":"Phio Pharmaceuticals Corp. reported quarter ended March 31, 2026 results: net income $4.0 million.","evidence_excerpt":"31, 2025. The increase in general and administrative expenses was primarily driven by employee related costs, investor outreach and professional fees. Net Loss Net loss was $ 4.0 million for the three months ended March 31, 2026 as compared with $1.8 million for the three months ended March 31, 2025. The increase in net loss was attributable to increases in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000143774926015590/0001437749-26-015590-index.htm","confidence":0.97,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2026"},{"label":"Net income","value":"$4.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}